• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Glide raises $4m for phase I trial of solid-dose teriparatide

February 1, 2017 By Sarah Faulkner

Glide TechnologiesGlide raises $4m for phase I trial of solid-dose teriparatide said today that it raised £3.2 million, or $4.0 million USD, in a round of financing. A number of existing investors contributed to the round, according to the Oxford-based company.

Glide plans to use the funds to finish phase I trials this year for its solid dose formulation of a parathyroid hormone, teriparatide.

“This new fundraising follows Glide’s successful octreotide clinical study last year and enables us to progress the clinical development of our pipeline as we move towards our goal of creating a patient-centric delivery platform integrating formulation science and device engineering,” interim CEO James Otter said in prepared remarks.

The phase I trials follow a successful pre-clinical study in which Glide’s solid dose formulation achieved a statistically similar pharmacokinetic profile to the most widely used clinical dose of the marketed liquid equivalent, Forteo.

Teriparatide is approved for use in the treatment of osteoporosis. The company’s pipeline includes octreotide, teriparatide, exenatide and anthrax and influenza vaccines.

Glide’s portfolio of pharmaceutical products are administered using its needle-free injector, the Glide SDI. The device removes the need for product refrigeration and cold chain distribution, according to the company, and could potentially improve compliance in long-term therapy and enhanced immune responses to vaccines.

In June last year, the company touted its preclinical study that compared its solid dose formulation of octreotide to a marketed immediate release liquid injectable product, Sandostatin.

The study compared the tolerability, pharmacokinetics and bioavailability of the 2 products. The data showed that Glide’s formulation achieved bioequivalence.

The 20-patient study also demonstrated that patients preferred using the SDI device compared to a needle or syringe delivery system.

Filed Under: Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Glide Technologies

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS